Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.33 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | ADH1A | P07327 | 2/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25976649 | 0.77 | NOD1 (0.47) | FOLH1 | |
| SCHEMBL22844805 | 0.77 | — | — | |
| SCHEMBL278867 | 0.77 | — | — | |
| SCHEMBL16557198 | 0.76 | FNTA (0.40) | FOLH1 | |
| SCHEMBL25773839 | 0.76 | MMP3 (0.32) | FOLH1 | |
| SCHEMBL23685458 | 0.76 | ALDH1A1 (0.41) | FOLH1 | |
| SCHEMBL10308346 | 0.76 | ALDH1A1 (0.41) | FOLH1 | |
| SCHEMBL16557197 | 0.75 | GSR (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL21029776 | 0.74 | — | — | |
| SCHEMBL26019590 | 0.72 | ECE1 (0.36) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | ADH1B 1840/4885ADH1C 3060/4885ADH1A 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.